First results of CAR-PRISM: early safety and efficacy of CAR-T in high-risk smoldering myeloma

Early findings from the CAR-PRISM trial of cilta-cel in high-risk smoldering myelomaПодробнее

CAR T-cell therapy for high-risk multiple myelomaПодробнее

Efficacy and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory Multiple MyelomaПодробнее

Initial results of cilta-cel, a CAR T-cell therapy, in earlier lines of treatmentПодробнее

Comparison of the safety & efficacy of CAR-T therapy vs bispecifics in R/R multiple myelomaПодробнее

Updated results of BCMA/CD19 dual-targeting fast CAR-T GC012F dual-targeting CAR-T in RRMMПодробнее

Safety and Efficacy of Fully Human BCMA CAR T Cells in Combination with a Gamma Secretase InhibitorПодробнее

Multiple Myeloma Precursor Conditions | Overview | Therapeutic InterventionПодробнее

Is CAR T-cell therapy being used to treat newly diagnosed multiple myeloma?Подробнее

CAR-T Cell Therapy Cilta-cel for Relapsed/Refractory Myeloma | Doris Hansen, MD | ASCO 2023Подробнее

Phase 1 Dual-Targeting FasTCAR-T Cells for First-Line Tx of Transplant-Eligible High-Risk MMПодробнее

Current use of CAR T-cell therapies in clinical practiceПодробнее

CAR T-cell therapy horizon scanПодробнее

Clinical Activity of BMS-986393, a CAR T cell therapy directed at GPRC5D, in Pts with RRMMПодробнее

What’s New Doc? End of the Year Updates on CAR T-cell Therapy in Multiple MyelomaПодробнее

What is CAR T-cell therapy and how does it work?Подробнее

Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Pts w/RR Multiple MyelomaПодробнее

International Myeloma Workshop 2021 | Daily Update, Part 2 | CAR-T Cell Therapy + Smoldering MMПодробнее

Using MRD status as a metric of CAR-T efficacy in patients with multiple myelomaПодробнее

What’s New Doc? End of the Year Updates on CAR T-cell Therapy in Multiple MyelomaПодробнее